telbivudine has been researched along with Body Weight in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, H; Shen, Y; Wang, Y; Zeng, H | 1 |
| Bao, W; Goodman, ZD; Jung, M; Lopez, P; Manns, MP; Naoumov, NV; Riva, A; Wedemeyer, H; Wursthorn, K | 1 |
2 other study(ies) available for telbivudine and Body Weight
| Article | Year |
|---|---|
Growth and development of children prenatally exposed to telbivudine administered for the treatment of chronic hepatitis B in their mothers.
Topics: Adult; Ankyloglossia; Antiviral Agents; Body Mass Index; Body Weight; Child Development; China; Delivery, Obstetric; Female; Hepatitis B Vaccines; Hepatitis B, Chronic; Humans; Infant; Infectious Disease Transmission, Vertical; Male; Maternal-Fetal Exchange; Mouth Abnormalities; Pregnancy; Pregnancy Complications, Infectious; Prenatal Exposure Delayed Effects; Reference Values; Telbivudine; Thymidine | 2015 |
Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients.
Topics: Adult; Antiviral Agents; Body Weight; Enzyme-Linked Immunosorbent Assay; Genotype; Hepatitis B Core Antigens; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Kinetics; Liver; Lymphocyte Activation; Nucleosides; Patient Selection; Pyrimidinones; Racial Groups; T-Lymphocytes; Telbivudine; Thymidine; Time Factors | 2010 |